Triple
T10837768
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Bruton tyrosine kinase |
E255805
|
entity |
| Predicate | isTherapeuticTargetOf |
P37016
|
FINISHED |
| Object |
acalabrutinib
Acalabrutinib is a second-generation, highly selective Bruton tyrosine kinase inhibitor used primarily in the treatment of certain B-cell malignancies such as mantle cell lymphoma and chronic lymphocytic leukemia.
|
E888598
|
NE FINISHED |
Provenance (5 batches)
| Stage | Batch ID | Job type | Status |
|---|---|---|---|
| creating | batch_69d6aa81a5d08190aa86689061d1ddd2 |
elicitation | completed |
| NER | batch_69d747002b3081908726901ee83d8f38 |
ner | completed |
| NED1 | batch_69deb139072081908a67e76a83575c32 |
ned_source_triple | completed |
| NED2 | batch_69deb4e471648190a00f3a921b5fb657 |
ned_description | completed |
| NEDg | batch_69deb41c9ae881909a3dab1292d6ddd7 |
nedg | completed |
Created at: April 8, 2026, 9:19 p.m.